Distinguished in Clear Cell Sarcoma

Dr. Leonard J. Appleman

Hematology Oncology | Oncology | Hematology
University Of Pittsburgh Physicians
5115 Centre Ave, 
Pittsburgh, PA 
Offers Telehealth
Distinguished in Clear Cell Sarcoma
University Of Pittsburgh Physicians
5115 Centre Ave, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leonard Appleman is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Appleman is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in PA
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Upmc St Margaret
Upmc Passavant
Excela Health Westmoreland Regional Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medical Mutual
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
5115 Centre Ave, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study
Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Elimusertib, Gemcitabine Hydrochloride, BAY 1895344
Study Phase: Phase 1
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma
A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Pembrolizumab, Tazemetostat
Study Phase: Phase 1/Phase 2
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Docetaxel
Study Phase: Phase 2
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drugs: Cediranib, Olaparib
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Eribulin Mesylate
Study Phase: Phase 2
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay
Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Other, Drug
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Enrollment Status: Completed
Publish Date: July 09, 2019
Intervention Type: Biological, Other
Study Phase: Phase 2
View 21 Less Clinical Trials

68 Total Publications

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 26, 2024
Similar Doctors
Distinguished in Clear Cell Sarcoma
Dr. Thomas Hogan
Hematology Oncology | Oncology
Distinguished in Clear Cell Sarcoma
Dr. Thomas Hogan
Hematology Oncology | Oncology

West Virginia University Medical Corporation

1 Medical Ctr Dr, 
Morgantown, WV 
 (55.4 miles away)
304-598-4865
Languages Spoken:
English
See accepted insurances

Thomas Hogan is a Hematologist Oncology specialist and an Oncologist in Morgantown, West Virginia. Dr. Hogan is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Renal Cell Carcinoma (RCC).

Distinguished in Clear Cell Sarcoma
Dr. David M. Friedland
Hematology Oncology | Oncology
Distinguished in Clear Cell Sarcoma
Dr. David M. Friedland
Hematology Oncology | Oncology
5115 Centre Ave, 3rd Floor, 
Pittsburgh, PA 
 (0.1 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances

David Friedland is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Friedland is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Distinguished in Clear Cell Sarcoma
Dr. Shifeng S. Mao
Hematology Oncology | Oncology
Distinguished in Clear Cell Sarcoma
Dr. Shifeng S. Mao
Hematology Oncology | Oncology

Allegheny Clinic Medical Oncology

1 Nolte Dr, 
Kittanning, PA 
 (31.5 miles away)
724-543-8657
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shifeng Mao is a Hematologist Oncology specialist and an Oncologist in Kittanning, Pennsylvania. Dr. Mao is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Appleman's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 10 Advanced Conditions
View All 53 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile